Metastatic breast cancer treatment: Difference between revisions
Jump to navigation
Jump to search
Jack Khouri (talk | contribs) |
Jack Khouri (talk | contribs) |
||
| Line 10: | Line 10: | ||
*The main aims of therapy are prolonging survival, improving quality of life and avoiding treatment-induced toxicity. Given that treatment is palliative, patients should be given treatment holidays in order to reduce drug-induced toxicity. | *The main aims of therapy are prolonging survival, improving quality of life and avoiding treatment-induced toxicity. Given that treatment is palliative, patients should be given treatment holidays in order to reduce drug-induced toxicity. | ||
*HER2 overexpression and hormone receptor status are very important factors that guide therapy and influence prognosis. | *HER2 overexpression and hormone receptor status are very important factors that guide therapy and influence prognosis. | ||
*Multiagent chemotherapy regimens don't show significant survival benefit compared to single-drug regimens. | *Multiagent chemotherapy regimens don't show significant survival benefit compared to single-drug regimens and augment toxicity. | ||
== References == | == References == | ||
Revision as of 22:14, 29 November 2011
|
Breast Cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Metastatic breast cancer treatment On the Web |
|
American Roentgen Ray Society Images of Metastatic breast cancer treatment |
|
Risk calculators and risk factors for Metastatic breast cancer treatment |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Assistant Editor-in-Chief Jack Khouri
Overview
With rare exception, metastatic breast cancer is an incurable but treatable illness. Currently, it is managed as a chronic disease, especially the category that is ER-positive with predominantly bone or soft tissue metastasis. Chemotherapy, biologic therapy and endocrine therapy are all considered in the treatment of meatastatic breast cancer.
Principles of therapy
- The main aims of therapy are prolonging survival, improving quality of life and avoiding treatment-induced toxicity. Given that treatment is palliative, patients should be given treatment holidays in order to reduce drug-induced toxicity.
- HER2 overexpression and hormone receptor status are very important factors that guide therapy and influence prognosis.
- Multiagent chemotherapy regimens don't show significant survival benefit compared to single-drug regimens and augment toxicity.